A detailed history of Susquehanna International Group, LLP transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 119,312 shares of LYEL stock, worth $131,243. This represents 0.0% of its overall portfolio holdings.

Number of Shares
119,312
Holding current value
$131,243
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.13 - $1.88 $134,822 - $224,306
119,312 New
119,312 $164,000
Q1 2024

May 07, 2024

SELL
$1.71 - $3.07 $336,531 - $604,182
-196,802 Reduced 41.05%
282,579 $630,000
Q4 2023

Feb 14, 2024

BUY
$1.39 - $2.35 $392,683 - $663,889
282,506 Added 143.5%
479,381 $929,000
Q3 2023

Nov 14, 2023

BUY
$1.45 - $3.35 $5,482 - $12,666
3,781 Added 1.96%
196,875 $289,000
Q2 2023

Aug 11, 2023

SELL
$1.89 - $3.86 $50,704 - $103,556
-26,828 Reduced 12.2%
193,094 $614,000
Q1 2023

May 16, 2023

BUY
$1.97 - $3.58 $324,275 - $589,293
164,607 Added 297.58%
219,922 $519,000
Q4 2022

Feb 14, 2023

SELL
$2.78 - $8.09 $183,240 - $533,244
-65,914 Reduced 54.37%
55,315 $191,000
Q3 2022

Nov 14, 2022

BUY
$5.54 - $8.27 $671,608 - $1 Million
121,229 New
121,229 $889,000
Q2 2022

Aug 15, 2022

SELL
$3.68 - $6.8 $162,858 - $300,934
-44,255 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$5.05 - $7.7 $171,477 - $261,461
33,956 Added 329.7%
44,255 $223,000
Q4 2021

Feb 14, 2022

SELL
$7.13 - $15.19 $154,835 - $329,866
-21,716 Reduced 67.83%
10,299 $80,000
Q3 2021

Nov 15, 2021

BUY
$11.0 - $17.95 $352,165 - $574,669
32,015 New
32,015 $474,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $273M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.